ICU Medical, Inc. (NASDAQ:ICUI) Given Average Recommendation of “Moderate Buy” by Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $176.50.

Several equities analysts recently commented on ICUI shares. KeyCorp cut their target price on ICU Medical from $191.00 to $173.00 and set an “overweight” rating for the company in a research report on Tuesday, October 21st. Piper Sandler raised their target price on ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. Finally, Raymond James Financial cut their target price on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a research report on Friday, August 8th.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain acquired 21,929 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was purchased at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the transaction, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. This trade represents a 20.26% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Greenberg acquired 1,200 shares of the business’s stock in a transaction on Wednesday, August 27th. The stock was acquired at an average price of $126.42 per share, with a total value of $151,704.00. Following the transaction, the director owned 7,960 shares in the company, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Evergreen Capital Management LLC grew its stake in ICU Medical by 27.4% in the third quarter. Evergreen Capital Management LLC now owns 2,094 shares of the medical instruments supplier’s stock valued at $251,000 after acquiring an additional 450 shares during the period. Pacific Capital Partners Ltd increased its stake in shares of ICU Medical by 19.0% during the third quarter. Pacific Capital Partners Ltd now owns 62,500 shares of the medical instruments supplier’s stock worth $7,498,000 after purchasing an additional 10,000 shares during the period. Nordea Investment Management AB grew its position in ICU Medical by 3.9% during the third quarter. Nordea Investment Management AB now owns 37,138 shares of the medical instruments supplier’s stock worth $4,318,000 after buying an additional 1,400 shares in the last quarter. SJS Investment Consulting Inc. boosted its holdings in shares of ICU Medical by 41,000.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 410 shares in the last quarter. Finally, Inspire Investing LLC boosted its holdings in shares of ICU Medical by 27.1% in the 3rd quarter. Inspire Investing LLC now owns 3,808 shares of the medical instruments supplier’s stock valued at $457,000 after purchasing an additional 812 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

Shares of ICUI stock opened at $120.11 on Wednesday. The stock has a 50 day moving average of $124.19 and a two-hundred day moving average of $128.93. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. ICU Medical has a 12 month low of $107.00 and a 12 month high of $196.26. The company has a market capitalization of $2.97 billion, a P/E ratio of -79.02 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping the consensus estimate of $1.44 by $0.66. The business had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.ICU Medical’s revenue was down 8.0% on a year-over-year basis. During the same quarter last year, the company earned $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities analysts expect that ICU Medical will post 4.11 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.